London IPO Market on Course for Best Year Since 2021 as UK Listings Narrative Shifts

The Quick Take

• The London Stock Exchange is on track for its best year for new listings since 2021, countering the prevailing narrative of UK capital market decline
• The Financial Times highlights that London's IPO performance is stronger than widely perceived, even as New York continues to attract higher-profile global listings
• Structural reforms including dual-class share structures and lighter-touch prospectus rules are beginning to improve London's competitive position as a listing venue

London's equity capital markets are mounting a quiet recovery from the post-Brexit listing drought, with the Financial Times reporting that the LSE is on course for its best year for new listings since 2021. The data point counters a dominant narrative that London is in terminal decline as a global IPO venue — a narrative reinforced by several high-profile company decisions to list or maintain primary listings in New York rather than the UK. The 2021 reference is significant: that year saw a wave of post-pandemic listings that created an artificially high baseline, making a comparable 2026 performance a meaningful statement about the durability of London's recovery rather than a one-off. UK capital markets reform — including dual-class share structures, SPAC reform, and a liberalized prospectus regime — appears to be providing the structural support that practitioners had argued was necessary.

For investors in UK financial infrastructure and domestically-focused growth companies, the London IPO market recovery has direct positive implications. The London Stock Exchange Group benefits through listing fees, index inclusion rebalancing, and the derivative trading volumes that accompany active primary issuance. UK investment banks — Barclays, HSBC, NatWest, and Lazard UK — recapture ECM advisory fees that had been migrating toward US-domiciled advisers following the listings exodus. For private equity funds with UK portfolio company assets, an improved London public market exit window reduces the pressure to pursue New York listings or accept below-target private sale valuations. The macro dynamic is that institutional investor confidence in UK earnings quality has improved alongside declining UK inflation and the Bank of England's rate-cutting cycle.

Key watch points for the London IPO recovery thesis include the H2 2026 listings pipeline — whether major deals expected in autumn 2026 successfully price and trade well in the aftermarket will determine whether institutional momentum sustains. The AS Watson (Superdrug owner) potential IPO delay is an immediate real-time test of whether large-cap Asian conglomerate appetite for London listings is genuinely returning or is still structurally impaired. The macro variable is the FTSE 100/250 valuation premium or discount to the S&P 500 — as long as UK public market multiples trade at a meaningful discount to comparable US companies, the structural incentive for founder-led and PE-backed companies to choose New York over London persists. Progress on narrowing that valuation gap is the underlying condition for a sustainable London IPO revival.

Synthesized from 1 source.